Generation of an anti-CD5 CAR knock-in human induced pluripotent stem cell line using CRISPR/Cas9 technology

Area of Science:

• Immunology
• Biotechnology
• Hematology

Background:

• Chimeric antigen receptor (CAR) T-cell therapy is a promising approach for hematologic malignancies.
• CD5 is a cell surface antigen expressed on malignant T-cells, making it a viable therapeutic target.
• Existing CAR T-cell therapies face challenges in targeting specific hematologic cancers.

Purpose of the Study:

• To develop a novel anti-CD5 CAR T-cell therapy for CD5-associated hematologic malignancies.
• To engineer a stable human induced pluripotent stem cell (iPSC) line expressing the anti-CD5 CAR construct.
• To validate the functionality and safety of the engineered iPSC line.

Main Methods:

• Utilized CRISPR/Cas9 gene editing technology for precise genetic modification.
• Generated a knock-in iPSC line stably expressing the anti-CD5 CAR construct.
• Employed FLAG tag and GFP markers for CAR expression detection and validation.

Main Results:

• Successfully generated a stable anti-CD5 CAR knock-in iPSC line.
• Confirmed stable CAR construct expression detectable via FLAG tag and GFP.
• Demonstrated maintenance of stem cell morphology, normal karyotype, and pluripotency markers.
• Confirmed retained differentiation potential of the engineered iPSC line.

Conclusions:

• The engineered anti-CD5 CAR iPSC line represents a viable platform for developing targeted T-cell therapies.
• This approach shows potential for treating CD5-associated hematologic malignancies like T-cell lymphoma and leukemia.
• The characterized iPSC line offers a foundation for further preclinical and clinical development of CAR T-cell therapies.